NEW YORK, March 16, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on OSUR, AIPT, TNDM, and TRXC which can be accessed for free by signing up to www.wallstequities.com/registration. Research reports have been initiated by WallStEquities.com on OraSure Technologies Inc. (NASDAQ: OSUR),
Bethlehem, Pennsylvania-based OraSure Technologies Inc.'s stock finished Thursday's session 0.98% lower at $18.28 with a total trading volume of 525,739 shares. Over the last month and the previous three months, the Company's shares have advanced 5.79% and 5.06%, respectively. Additionally, the stock has gained 61.48% over the past year. Shares of the Company are trading below their 200-day moving average by 2.50%. Moreover, shares of OraSure Technologies, which together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the US, Europe, and internationally, have a Relative Strength Index (RSI) of 49.03. Get the full research report on OSUR for free by clicking below at:
Shares in Eagan, Minnesota-based Precision Therapeutics Inc. declined 3.94%, ending yesterday's session at $1.22 with a total trading volume of 210,625 shares. The stock has gained 11.93% in the past month and 13.90% in the previous three months. The Company's shares are trading 13.76% above their 50-day moving average. Moreover, shares of Precision Therapeutics, which manufactures environmentally conscientious system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care in the US, have an RSI of 54.27.
On March 12th, 2018, Precision Therapeutics announced that it has appointed Kevin Hungerford as Global Vice President of Sales and Marketing, effective immediately. Based in the US, Mr. Hungerford will be responsible for overseeing all sales and marketing activities for the Company's FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal to hospitals and medical centers. He will report to Dr. Carl Schwartz, CEO, and replaces Mr. Peter Alex, who is stepping down to pursue other opportunities. Find your free research report on AIPT at:
Tandem Diabetes Care
On Thursday, San Diego, California headquartered Tandem Diabetes Care Inc.'s stock saw a slight decline of 0.52%, to close the day at $3.86. A total volume of 480,253 shares was traded. The Company's shares have advanced 58.85% in the last month and 53.78% in the previous three months. The stock is trading 27.55% above its 50-day moving average. Additionally, shares of the Company, which designs, develops, and commercializes various products for people with insulin-dependent diabetes in the US, have an RSI of 64.09.
On March 07th, 2018, Tandem Diabetes Care announced that Kim Blickenstaff, President and CEO, will present a Company update at the 28th Annual Oppenheimer Healthcare Conference in New York. The presentation will take place on March 21st, 2018, at 11:30 a.m. ET. The presentation will be webcast live and will be accessible on the Company's Investor Center website. Sign up today for the free research report on TNDM at:
Shares in Morrisville, North Carolina headquartered TransEnterix Inc. ended the day 5.68% lower at $1.66. A total volume of 1.69 million shares was traded. The stock has gained 24.81% in the last month and 49.55% over the past year. The Company's shares are trading above their 200-day moving average by 7.71%. Furthermore, shares of TransEnterix, which focuses on the development and commercialization of surgical robotic systems, have an RSI of 45.09.
On March 06th, 2018, TransEnterix announced its results for the quarter and year ended December 31st, 2017. For Q4 2017, revenue was $3.4 million, total operating expenses were $17.8 million, and net loss was $76.2 million. For the full year 2017, revenue was $7.1 million, total operating expenses were $62.3 million, and net loss was $144.8 million. The Company had cash and restricted cash of approximately $97.6 million as of December 31st, 2017. Wall St. Equities' research coverage also includes the downloadable free report on TRXC at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/free-research-reports-on-these-medical-supplies-stocks----orasure-technologies-precision-therapeutics-tandem-diabetes-care-and-transenterix-300615185.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!